Both groups, DM-1 monotherapy and DTIC+DM-1, revealed a tumor burden reduction of about 60%, partly via cell cycle arrest due to cyclin D1 and Ki67 decrease [8]. This evidence concerns the gene MKI67 and neoplasm.